Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study

Cancer Communications

Ming-Shyen Yen¹  Wei-Pin Chang²  Chien-Hsing Lu²  Wai-Hou Lee³  Chi-Mu Chuang⁴  Yen-Hou Chang⁴  Yi Chang⁵ 

[1] Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, China;Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, China;Institute of Biomedical Sciences, National Chung Hsing University, Taichung, China;Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, China;Rong-Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, China

关键词: Epithelial ovarian, tubal, and peritoneal cancer;    Intraperitoneal chemotherapy;    Propensity score;    Survival;    Clinical trials;   

DOI  :  10.1186/s40880-016-0105-3

学科分类：肿瘤学

来源: Springer

【 摘 要 】

We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

【 授权许可】

CC BY